National Institutes of Health (nih)

Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk B-cell acute lymphoblastic leukemia (B-ALL), with a 3-year DFS of 96%.

Adding BLINCYTO to chemotherapy significantly improves disease-free survival in pediatric patients with B-cell acute lymphoblastic leukemia, with a 3-year DFS of 96% compared to 87.9% with chemotherapy alone.

Adding BLINCYTO (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL), with a 3-year DFS of 96% compared to 87.9% with chemotherapy alone.

GeNeuro presented groundbreaking findings on GNK-301, a precision medicine strategy for ALS targeting HERV-K ENV neurotoxic protein, at the 35th International Symposium on ALS/MND in Montreal.

MassBio anticipates policy shifts under a new administration, focusing on healthcare priorities, regulatory changes, and biotech industry support. Key concerns include potential price controls under the Inflation Reduction Act, the BIOSECURE Act's impact on biosecurity, and PBM reform. MassBio also highlights the importance of IP protection, tax reform, and M&A in biotech growth. The organization remains committed to advocating for innovation, scientific integrity, and patient access to life-saving therapies.

The Nano Biotechnology Market is projected to grow from USD 5.65 billion in 2023 to USD 12.99 billion by 2032, driven by advancements in diagnostics, therapeutics, and public health innovations.

The Nano Biotechnology Market was valued at USD 5.65 billion in 2023 and is projected to reach USD 12.99 billion by 2032, growing at a CAGR of 9.71%. The market is driven by the increasing use of nanomaterials in pharmaceuticals, medical devices, and diagnostics, enhancing efficacy and precision. Key players include Ablynx, Nami Therapeutics, and Celgene Corporation. North America leads the market, with strong investments in R&D and advanced healthcare infrastructure.

The global HIV clinical trials market is projected to grow from USD 1.30 billion in 2024 to USD 2.42 billion by 2034, at a CAGR of 6.4%. Key factors driving growth include increasing HIV infections, R&D investments, drug approvals, and HIV vaccine trials. Phase I trials held the largest revenue share in 2024, while the Asia Pacific region is expected to register the fastest growth. Major companies like Gilead Sciences and Janssen Global Services are significant contributors to the market.

The Biden-Harris Administration has made significant progress in ending the HIV epidemic through a whole-of-society approach, including expanding access to HIV prevention and treatment, strengthening global efforts, ensuring equitable healthcare, increasing awareness, and prioritizing community-driven responses. Key achievements include a 12% decrease in HIV incidence in the U.S. since 2018, 25 million lives saved by PEPFAR, and 2.5 million people on PrEP globally. The administration continues to focus on advancing science, equity, and ending stigma and discrimination.

Trump's healthcare picks, including anti-vaccine activist Robert Kennedy Jr for HHS, spark debate. Kennedy's appointment led to health stock drops and vows to overhaul NIH and FDA. Other nominees include lockdown opponents Jay Bhattacharya for NIH, Dave Weldon for CDC, and Marty Makary for FDA. Celebrity doctor Mehmet Oz is tapped to lead CMS, and Fox News' Janette Nesheiwat is chosen for Surgeon General.